, APA/dpa-AFX

GNW-Adhoc: Idorsia thanks Guy Braunstein for his years of service as he retires

^* Guy Braunstein, currently Chief Medical Officer and member of the Idorsia

Executive Committee, to retire at the end of March 2024

Allschwil, Switzerland - March 22, 2024

Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as

Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development

and member of the Idorsia Executive Committee since the creation of Idorsia will

retire at the end of March 2024. Guy will continue to support Idorsia as an

advisor, especially in the analysis and interpretation of the data coming from

the programs that he has initiated and led during his time with the company.

Jean-Paul Clozel, MD and Chief Executive Officer of Idorsia commented:

"Over the last 15 years, Guy has made a huge contribution to Idorsia and to

Actelion before that. As Head of Global Clinical Development until 2022, Guy was

instrumental in successfully steering several drugs in several very different

indications from rare diseases and specialty indications, such as pulmonary

arterial hypertension, lysosomal disorders, and multiple sclerosis, to public

health issues including insomnia and hypertension, through to approval. In his

most recent role as Chief Medical Officer, Guy was critical in unifying the

company's quality and governance standards to ensure an uncompromisingly ethical

and scientifically rigorous approach along the lifecycle of all products in

Idorsia's pipeline. I am very happy that we can continue to benefit from Guy's

vast experience after his retirement since he will serve as an advisor to

Idorsia."

Guy Braunstein, MD, PhD, and Chief Medical Officer of Idorsia commented:

"It has been an absolute privilege to work with an outstanding team of experts

who are all dedicated to improving peoples' lives with innovative medicines. I

believe that bringing new drugs to prescribers and having a real impact on

patients is one of the most rewarding endeavors. Having worked as a

pulmonologist practitioner for a number of years, and joined the pharmaceutical

industry in 1988, I am very proud of all that we have achieved over the past 15

years of my career at Actelion and Idorsia. I am satisfied that the clinical

development is in safe hands with Alberto Gimona and, with the support of

Antonio Olivieri, that we have all the correct checks and balances in place to

ensure appropriate and safe use of Idorsia's medicinal products and medical

ethics in engagement with various stakeholders. I am therefore ready to hand the

reigns over and start my retirement. I am also very happy to stay involved in

the projects that have given me such job satisfaction over the years."

The CMO role was created in 2022 to ensure that Idorsia's approach to medical

governance and its policies and procedures are globally aligned and consistent

across Drug Discovery, Clinical Development, Pharmaceutical Development and

Global and Local Medical Affairs. From April 1(st), the CMO role will be assumed

by Antonio Olivieri, who will continue to lead the Global Medical Affairs

function of Idorsia, merging with Global Clinical Development reporting into

Alberto Gimona, Head of Global Clinical Development & Medical Affairs, and

member of the Idorsia Executive Committee.

Jean-Paul continued:

"I am very pleased that with Antonio, we already have the ideal candidate to

succeed Guy from within our ranks. Antonio joined Idorsia in 2020 and built our

Global Medical Affairs function from the ground up. In his new role as Chief

Medical Officer, Antonio will continue to ensure that we maintain our focus on

ethical excellence and communicating to the medical community about our

innovative portfolio."

Notes to the editor

About Idorsia

Idorsia Ltd is reaching out for more - We have more ideas, we see more

opportunities and we want to help more patients. In order to achieve this, we

will develop Idorsia into a leading biopharmaceutical company, with a strong

scientific core.

Headquartered near Basel, Switzerland - a European biotech-hub - Idorsia is

specialized in the discovery, development and commercialization of small

molecules to transform the horizon of therapeutic options. Idorsia has a 20-year

heritage of drug discovery, a broad portfolio of innovative drugs in the

pipeline, an experienced team of professionals covering all disciplines from

bench to bedside, and commercial operations in Europe and North America - the

ideal constellation for bringing innovative medicines to patients.

Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June 2017

and has over 800 highly qualified specialists dedicated to realizing our

ambitious targets.

For further information, please contact

Andrew C. Weiss

Senior Vice President, Head of Investor Relations & Corporate Communications

Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil

+41 58 844 10 10

investor.relations@idorsia.com (mailto:investor.relations@idorsia.com)

media.relations@idorsia.com

www.idorsia.com (http://www.idorsia.com)

The above information contains certain "forward-looking statements", relating to

the company's business, which can be identified by the use of forward-looking

terminology such as "estimates", "believes", "expects", "may", "are expected

to", "will", "will continue", "should", "would be", "seeks", "pending" or

"anticipates" or similar expressions, or by discussions of strategy, plans or

intentions. Such statements include descriptions of the company's investment and

research and development programs and anticipated expenditures in connection

therewith, descriptions of new products expected to be introduced by the company

and anticipated customer demand for such products and products in the company's

existing portfolio. Such statements reflect the current views of the company

with respect to future events and are subject to certain risks, uncertainties

and assumptions. Many factors could cause the actual results, performance or

achievements of the company to be materially different from any future results,

performances or achievements that may be expressed or implied by such forward-

looking statements. Should one or more of these risks or uncertainties

materialize, or should underlying assumptions prove incorrect, actual results

may vary materially from those described herein as anticipated, believed,

estimated or expected.

°

 ISIN  CH0363463438

AXC0051 2024-03-22/07:05

Relevante Links: Idorsia Ltd

Copyright APA/dpa-AFX. Alle Rechte vorbehalten. Weiterverbreitung, Wiederveröffentlichung oder dauerhafte Speicherung ohne ausdrückliche vorherige Zustimmung von APA/dpa-AFX ist nicht gestattet.